期刊
JOURNAL OF CONTROLLED RELEASE
卷 311, 期 -, 页码 257-272出版社
ELSEVIER
DOI: 10.1016/j.jconrel.2019.08.038
关键词
Bone metastasis; Breast cancer; Nanoparticle; Gli2; PTHrP; GANT58
资金
- NCI/NIH [U01CA091664, 5P30 CA68485-19]
- NIH [R00CA194198, R01CA163499]
- VA Merit Award [1I01BX001957]
- DOD CDMRP [W81XWH-18-1-0029, W81XWH15-1-0627, W81XWH-15-1-0622]
- [1S10RR027027631]
Solid tumors frequently metastasize to bone and induce bone destruction leading to severe pain, fractures, and other skeletal-related events (SREs). Osteoclast inhibitors such as bisphosphonates delay SREs but do not prevent skeletal complications or improve overall survival. Because bisphosphonates can cause adverse side effects and are contraindicated for some patients, we sought an alternative therapy to reduce tumor-associated bone destruction. Our previous studies identified the transcription factor Gli2 as a key regulator of parathyroid hormone-related protein (PTHrP), which is produced by bone metastatic tumor cells to promote osteoclast-mediated bone destruction. In this study, we tested the treatment effect of a Gli antagonist GANT58, which inhibits Gli2 nuclear translocation and PTHrP expression in tumor cells. In initial testing, GANT58 did not have efficacy in vivo due to its low water solubility and poor bioavailability. We therefore developed a micellar nanoparticle (NP) to encapsulate and colloidally stabilize GANT58, providing a fully aqueous, intravenously injectable formulation based on the polymer poly(propylene sulfide)(135)-b-poly[(oligoethylene glycol)(9) methyl ether acrylate](17)(PPS135-b-POEGA(17)). POEGA forms the hydrophilic NP surface while PPS forms the hydrophobic NP core that sequesters GANT58. In response to reactive oxygen species (ROS), PPS becomes hydrophilic and degrades to enable drug release. In an intratibial model of breast cancer bone metastasis, treatment with GANT58-NPs decreased bone lesion area by 49% (p < .01) and lesion number by 38% (p < .05) and resulted in a 2.5-fold increase in trabecular bone volume (p < .001). Similar results were observed in intracardiac and intratibial models of breast and lung cancer bone metastasis, respectively. Importantly, GANT58-NPs reduced tumor cell proliferation but did not alter mesenchymal stem cell proliferation or osteoblast mineralization in vitro, nor was there evidence of cytotoxicity after repeated in vivo treatment. Thus, inhibition of Gli2 using GANT58-NPs is a potential therapy to reduce bone destruction that should be considered for further testing and development toward clinical translation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据